ERBB2 and sarcoma: Several clinical trials are currently active testing HER2 CAR-Ts for the treatment of several HER2-positive tumors aside from breast, such as brain malignancies (NCT02442297, NCT01109095, NCT03500991), sarcomas (NCT04995003, NCT00902044), lung cancer (NCT03198052), pleural and peritoneal metastasis (NCT04684459), ependymoma (NCT04903080), and pancreas tumors (NCT01935843).